The Company will accelerate the commercial deployment of its Artificial Intelligence reading solution for 2D/3D mammography, with a focus on the United StatesPARIS, NICE, France and CHICAGO, May 12, 2022 /PRNewswire/ -- Therapixel, designer and supplier of MammoScreen® an Artificial Intelligence software reading aid for mammography, announces today fundraising of 15 M€ in series B. MammoscreenThis operation was led by Crédit Mutuel Innovation and CapHorn, joined by Verve, Sham Innovation Santé and historical investors Omnes, IT-Translation, M-Capital and Région Sud Investissement. We are very happy to support Therapixel's commercial expansion in the United States, and help the company establish a new standard in breast cancer detection. This fundraising will enable Therapixel to accelerate its commercial presence in the United States, launch more unique features for MammoScreen, and push even further the boundaries of its intelligent reading aid for mammography. Winner of the Digital Mammography DREAM Challenge in 2017, the global competition on breast cancer detection with AI, Therapixel has developed MammoScreen®, a software that helps with the interpretation of screening 2D and 3D mammograms.